These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

544 related items for PubMed ID: 29719121

  • 1. A Focus on Macitentan in the Treatment of Pulmonary Arterial Hypertension.
    Bedan M, Grimm D, Wehland M, Simonsen U, Infanger M, Krüger M.
    Basic Clin Pharmacol Toxicol; 2018 Aug; 123(2):103-113. PubMed ID: 29719121
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro.
    Angus JA, Soeding PF, Hughes RJA, Wright CE.
    Eur J Pharmacol; 2017 Jun 05; 804():111-116. PubMed ID: 28300593
    [Abstract] [Full Text] [Related]

  • 4. Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
    Grünig E, Ohnesorge J, Benjamin N, Burhenne J, Enderle Y, Egenlauf B, Fischer C, Harutyunova S, Huppertz A, Klose H, Haefeli WE.
    Respiration; 2017 Jun 05; 94(1):26-37. PubMed ID: 28494463
    [Abstract] [Full Text] [Related]

  • 5. Comparative adherence of macitentan versus ambrisentan and bosentan in Australian patients with pulmonary arterial hypertension: a retrospective real-world database study.
    Lau E, Kotlyar E, Makanji Y, Yu DY, Tan JY, Casorso J, Kouhkamari MH, Lim S, Wu DB, Bloomfield P.
    J Med Econ; 2024 Jun 05; 27(1):596-604. PubMed ID: 38488130
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Dynamics of the clinical functional and hemodynamic profile of patients with pulmonary arterial hypertension with initial monotherapy with endothelin receptor antagonists: bosentan vs. macitentan].
    Martynyuk TV, Aleevskaya AM.
    Kardiologiia; 2020 Aug 11; 60(7):28-35. PubMed ID: 33155938
    [Abstract] [Full Text] [Related]

  • 11. Comparative efficacy and acceptability of endothelin receptor antagonists for pulmonary arterial hypertension: A network meta-analysis.
    Duo-Ji MM, Long ZW.
    Int J Cardiol; 2017 May 01; 234():90-98. PubMed ID: 28233631
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P, Coghlan G.
    Drugs; 2008 May 01; 68(12):1635-45. PubMed ID: 18681488
    [Abstract] [Full Text] [Related]

  • 14. Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesis.
    Gatfield J, Mueller Grandjean C, Bur D, Bolli MH, Nayler O.
    PLoS One; 2014 May 01; 9(9):e107809. PubMed ID: 25226600
    [Abstract] [Full Text] [Related]

  • 15. Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.
    Jansa P, Pulido T.
    Am J Cardiovasc Drugs; 2018 Feb 01; 18(1):1-11. PubMed ID: 29280064
    [Abstract] [Full Text] [Related]

  • 16. Macitentan (Opsumit) for the treatment of pulmonary arterial hypertension.
    Clarke M, Walter C, Agarwal R, Kanwar M, Benza RL.
    Expert Rev Clin Pharmacol; 2014 Jul 01; 7(4):415-21. PubMed ID: 24851934
    [Abstract] [Full Text] [Related]

  • 17. Macitentan for the treatment of pulmonary arterial hypertension.
    DuBrock HM, Channick RN.
    Expert Rev Respir Med; 2014 Aug 01; 8(4):393-9. PubMed ID: 24998329
    [Abstract] [Full Text] [Related]

  • 18. Comparison of pharmacological activity of macitentan and bosentan in preclinical models of systemic and pulmonary hypertension.
    Iglarz M, Bossu A, Wanner D, Bortolamiol C, Rey M, Hess P, Clozel M.
    Life Sci; 2014 Nov 24; 118(2):333-9. PubMed ID: 24582812
    [Abstract] [Full Text] [Related]

  • 19. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.
    Aversa M, Porter S, Granton J.
    Drug Saf; 2015 May 24; 38(5):419-35. PubMed ID: 25792028
    [Abstract] [Full Text] [Related]

  • 20. Macitentan: A Review in Pulmonary Arterial Hypertension.
    Keating GM.
    Am J Cardiovasc Drugs; 2016 Dec 24; 16(6):453-460. PubMed ID: 27580996
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.